BLPH vs. HSTO, CMRA, EVFM, SXTC, SPRC, APVO, ADTX, EVLO, SBFM, and ATHX
Should you be buying Bellerophon Therapeutics stock or one of its competitors? The main competitors of Bellerophon Therapeutics include Histogen (HSTO), Comera Life Sciences (CMRA), Evofem Biosciences (EVFM), China SXT Pharmaceuticals (SXTC), SciSparc (SPRC), Aptevo Therapeutics (APVO), Aditxt (ADTX), Evelo Biosciences (EVLO), Sunshine Biopharma (SBFM), and Athersys (ATHX). These companies are all part of the "pharmaceutical preparations" industry.
Histogen (NASDAQ:HSTO) and Bellerophon Therapeutics (NASDAQ:BLPH) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, analyst recommendations, risk, profitability, valuation, earnings, community ranking and dividends.
Bellerophon Therapeutics has a consensus price target of $2.00, suggesting a potential upside of 3,452.40%. Given Histogen's higher probable upside, analysts plainly believe Bellerophon Therapeutics is more favorable than Histogen.
Histogen has a beta of 0.91, suggesting that its stock price is 9% less volatile than the S&P 500. Comparatively, Bellerophon Therapeutics has a beta of 0.69, suggesting that its stock price is 31% less volatile than the S&P 500.
10.6% of Bellerophon Therapeutics shares are held by institutional investors. 3.3% of Histogen shares are held by insiders. Comparatively, 5.2% of Bellerophon Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Bellerophon Therapeutics received 312 more outperform votes than Histogen when rated by MarketBeat users. Likewise, 60.42% of users gave Bellerophon Therapeutics an outperform vote while only 58.33% of users gave Histogen an outperform vote.
Bellerophon Therapeutics has a net margin of 0.00% compared to Bellerophon Therapeutics' net margin of -65,142.11%. Bellerophon Therapeutics' return on equity of -136.13% beat Histogen's return on equity.
In the previous week, Bellerophon Therapeutics had 1 more articles in the media than Histogen. MarketBeat recorded 1 mentions for Bellerophon Therapeutics and 0 mentions for Histogen. Bellerophon Therapeutics' average media sentiment score of 0.00 equaled Histogen'saverage media sentiment score.
Histogen has higher revenue and earnings than Bellerophon Therapeutics. Histogen is trading at a lower price-to-earnings ratio than Bellerophon Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Bellerophon Therapeutics beats Histogen on 9 of the 14 factors compared between the two stocks.
Get Bellerophon Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for BLPH and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BLPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Bellerophon Therapeutics Competitors List
Related Companies and Tools
